Clinical trial · Interventional
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
NCT05707182CI-TRIAL-00081013withdrawnEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Recruitment was difficult.
Summary
Brief summary (as posted)
The purpose of this study is to investigate the usefulness of PET/MRI with an investigational radioactive drug, 18F-rhPSMA-7.3, and MRI contrast in evaluating patients with prostate cancer eligible for active surveillance. This study is for imaging purposes only and is not a treatment study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-rhPSMA-7.3 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Prostate Cancer
- description
- 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study
- interventionNames
- Drug: 18F-rhPSMA-7.3
Primary outcomes (1)
- measure
- Number of lesions detected in total on the participants' mpMRI exams.
- timeFrame
- through study completion, average 1 year
Secondary outcomes (1)
- measure
- Number of lesions detected on the participants' 18F-rhPSMA-7.3 exams.
- timeFrame
- through study completion, average 1 year
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Men with biopsy-confirmed low risk or favorable intermediate risk prostate cancer who are scheduled to undergo multiparametric prostate MRI and confirmatory biopsy as per institutional active surveillance protocol. Exclusion Criteria: * Biopsy-proven prostate cancer not eligible for active surveillance per institutional criteria. * Current or prior treatment for prostate cancer. * Suspected prostate cancer without histologic confirmation. * Inability to undergo 3 Tesla prostate MRI due to claustrophobia and/or MRI- incompatible devices or MR incompatible metal implants.
References
Publications (0)
Data not yet available
No reference posted for this study.